RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.6776

Change

+0.53 (+4.34)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+1.04 (+2.22%)

USD 1.42B
PSQ ProShares Short QQQ

+1.03 (+2.45%)

USD 0.67B
SPXU ProShares UltraPro Short S&P50..

+1.94 (+7.01%)

USD 0.52B
SOXS Direxion Daily Semiconductor B..

+1.38 (+5.25%)

USD 0.46B
YANG Direxion Daily FTSE China Bear..

+0.21 (+0.44%)

USD 0.27B
SDOW ProShares UltraPro Short Dow30

+4.55 (+7.58%)

USD 0.23B
RWM ProShares Short Russell2000

+0.46 (+2.10%)

USD 0.21B
FNGD MicroSectors FANG+ Index -3X I..

+1.18 (+7.11%)

USD 0.18B
SPDN Direxion Daily S&P 500® Bear ..

+0.27 (+2.22%)

USD 0.18B
DOG ProShares Short Dow30

+0.70 (+2.43%)

USD 0.14B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.53% 47% F 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.53% 47% F 90% A-
Trailing 12 Months  
Capital Gain 9.87% 89% A- 82% B
Dividend Return 2.53% 62% D 45% F
Total Return 12.40% 89% A- 82% B
Trailing 5 Years  
Capital Gain -56.48% 80% B- 7% C-
Dividend Return 3.00% 77% C+ 6% D-
Total Return -53.48% 80% B- 6% D-
Average Annual (5 Year Horizon)  
Capital Gain 66.40% 39% F 96% N/A
Dividend Return 67.84% 39% F 96% N/A
Total Return 1.44% 62% D 35% F
Risk Return Profile  
Volatility (Standard Deviation) 433.06% 63% D 3% F
Risk Adjusted Return 15.66% 54% F 33% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.